Roche said MS drug Ocrevus should generate sales of CHF2bn in its first full year after launch. The Swiss group also pledged to actively help the Trump Administration with its healthcare reform program.

German Merck tells Scrip Mavenclad's long spell in the regulatory 'wilderness' allowed it to amass deep safety and efficacy data that should help the oral MS drug's commercial prospects.

German Merck tells Scrip its quest to find a partner for its Bruton’s tyrosine kinase inhibitor evobrutinib should be helped by positive 24-week Phase IIb data in relapsing multiple sclerosis.

Analysts shrugged off mixed topline data from a Phase II study showing Xencor’s lead compound XmAb5871 missed its primary endpoint in systemic lupus erythematosus (SLE), blaming the miss on the number of patients dropping out of the placebo arm of the trial.  

VelosBio's well-backed Series A funding round showed that investors believe his team has identified the right combination of cancer target, linker and payload for creating a successful novel ADC, the biotech's CEO told Scrip.

AI is already transforming healthcare. But a successful evolution of machine learning in the sector demands ethical and practicable regulations that ensure public trust and a road map for innovative companies and end-users, a London conference heard. Scrip was there.